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Abstract: This study was carried out for evaluating the interplay of p53, p21 and Ki-67 proteins along 
the colorectal adenoma-carcinoma oncogenic transformation sequel. Therefore, Fifty colorectal cancer 
and 14 adenoma patients were involved. The histopathological expression of p53, p21 and Ki-67 
proteins was evaluated by immunohistochemistry assay. The results revealed that remarkable 
overexpression of p53 protein was seen in the tumorous sections of cancer patients more than that in 
adenoma patients (p<0.05), while no p53 overexpression was found in the corresponding non-
tumorous sections. The positive expression of p21 protein was lower in the tumorous sections of 
cancer patients than that of adenoma patients (p<0.05) and was higher in the non-tumorous than the 
corresponding tumorous sections of both CRC and adenoma patients (p<0.05). The expression of p53 
and p21 proteins in cancer patients was inversely correlated to each other (p<0.05) and the expression 
of p21 rather than p53 protein was associated with colorectal cancer staging and grading (p<0.05). Ki-
67 was higher in cancer than in adenoma patients and higher in the tumorous tissue sections than the 
corresponding non-tumorous sections (p<0.05). The overexpression of p53 and downexpression of p21 
proteins in colorectal cancer might be responsible largely for triggering the transformational changes in 
normal mucosa to develop adenoma and trigger also the malignant cascade from adenoma to 
carcinoma. P53 overexpression was shown to occur due to the mutated dysfunctional p53 gene product 
which loses its transcriptional activator necessary for p21 expression. The level of p21 protein which is 
a quantitatively affected by the loss of p53 activation is responsible for the association with cancer 
staging and grading that serves as a good indicator for the disease progression. 
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INTRODUCTION 
 
 Colorectal Cancer (CRC) is the fourth commonest 
form of cancer occurring worldwide. The number of 
new cases of colorectal cancer has been increasing 
rapidly since 1975[1]. Risks for developing colorectal 
cancer include having inflammatory bowel disease, a 
personal or family history of colorectal cancer or 
colorectal polyps and certain hereditary syndromes. 
There is strong evidence that most invasive colorectal 
adenocarcinomas arise in pre-existing adenomatous 
polyps. The malignant risk with an adenomatous polyp 
is correlated with 3 interdependent features, polyp size, 
histology and severity of epithelial dysplasia[2]. 
 In vast majority, CRC arise through a series of 
genetic mutations that activates proto-oncogenes and 
disable tumor suppressor genes resulting in the normal 
colonic epithelium to give way to precancerous 
adenoma development and eventually frank 
adenocarcinoma[3]. In last decades it has been 
confirmed that sporadic CRC originate from colorectal 
adenoma, through adenoma-carcinoma sequence[4,5] and 
colorectal adenomas are fairly common in the general 
population in that 40% of the western population will 
have colorectal adenoma[6,7], but only 5-10% progress 
to a malignant tumor[5,8]. And recent work continues to 
support the adenoma-carcinoma sequence, however 
there is a paucity of data on the interrelationship 
between different genetic mutations and on the 
relationship between molecular and other types of 
genetic abnormalities[9]. It was demonstrated that 
colorectal tumor initiation and progression requires at 
least seven different somatic changes before a cell can 
develop into a carcinoma[10]. Cancers arise from the 
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sequential acquisition of genetic alterations in specific 
genes. The high number of mutations in cancer cells led 
to the hypothesis that an early step in tumor progression 
is the generation of a genetic instability[11]. Missense 
mutations in the p53 tumor suppressor gene on the 
remaining chromosome 17 are found in more than 80% 
of CRC and represent a late event in the adenoma-
carcinoma sequence[12-14]. P53 acts as a checkpoint 
control protein that determines cellular fate upon DNA 
damages[15,16]. It can delay the progression of the cell 
cycle from G1 to S phase, thus allowing for repair of 
DNA damage[5,17]. Alternatively, p53 can trigger 
apoptosis in response to DNA damage, most probably 
when the lesions are too extensive and DNA repair 
fails[16,18] . Loss of p53 tumor suppressor activity, 
results in cells tolerating DNA damage that can occur 
by genotoxic products, which eventually may lead to 
cancer formation due to inability to eliminate damaged 
cells by apoptosis[19] . 
 Another tumor suppressor protein is p21, which 
was identified as the product of the gene activated by 
wild-type p53 and it was named also WAF1 (wild-type 
p53 activated factor) [20-22]. The normal cell cycle is 
significantly controlled by cyclins and Cyclin 
Dependent Kinases (CDK) and The balance between 
CDK activation and inactivation determines whether 
cells proceed through G1 into S phase and from G2 to 
M, through regulatory mechanisms that are conserved 
in more complex eukaryotes[23]. However, their 
influence is only effective in the G1 phase, especially 
during the transition into the S phase[24]. This part of the 
cell cycle is a restriction point, since all other cell cycle 
compartments cannot be modified by interference with 
diverse proteins or enzymes. In this context, 
p21/waf1/cip1 has been shown to act as a CDK 
inhibitor and is located on chromosome 6 in position 
p21[16-20]. P21/waf1/cip1 inhibits the CDK 2, 3, 4 and 6, 
thus controlling the cell cycle at the G1 phase including 
the restriction point[25]. Furthermore, It was found that 
transfection of p21 cDNA suppresses the growth of 
some normal tissues and tumor cells[26]. 
 Cell proliferation is regarded as one of the most 
important biological mechanisms in oncogenesis. 
Proliferating cell nuclear antigen (PCNA) and Ki-67 are 
the most popular methods that have been investigated 
as prognostic factors in colorectal cancer[27]. There is 
strong evidence that Ki-67 expression correlates with 
cell proliferation as measured by S and G2 fractions[28]. 
High proliferation (Ki-67 50%) was proved to be 
reliable and reproducible index. CRC patients with 
lesions with higher Ki-67 expression had significantly 
decreased survival than their counterparts, with lesions 
expressing lower levels of Ki-67[29]. 
 Many studies were done on the role of p53, p21 
and ki-67 on CRC[30-36] but no previous study focused 
in detail on the role of the paradoxical changes in the 
expression of p53 and p21 proteins by examining both 
the tumorous and non-tumorous, safe margins, tissue 
sections in both colorectal adenoma and carcinoma 
tissue sections and comparing all the studied variables 
with each other in one study. In this study, we aimed at 
investigating particularly the interplay between p53 and 
p21 proteins expression in both tumorous and non-
tumorous, safe margin, tissue sections along the 
progression pathway of colorectal adenoma to 
carcinoma in order to shed light on, the nature of 
expression of tumor suppression proteins that 
predispose to CRC development from adenomas and 
development of adenoma from normal mucosa, 
understand the interplay between p53 and p21 proteins 
and their roles in the progression of the disease, 
understand the nature of the functional status of p53 
responsible for the adenoma-carcinoma transformation 
process. The carcinogenic proliferative changes driven 
largely by the changed expression of p53 and p21 
proteins are best measured by Ki-67 protein expression. 
The obtained results could offer a better understanding 
of the entangled role of the oncogenic, proliferative and 
tumor suppressor factors in predisposing or causing 
CRC in human beings. 
 
MATERIALS AND METHODS 
 
Patients involved and samples collected in this 
study: In the period from January 2007 to February 
2008, 50 patients with primary CRC who underwent 
elective surgical resection of colorectal cancer in 
Selangor state were involved in this study before 
application of any chemotherapy. Excisional biopsy 
was taken postoperatively and 2 sets of tissue sections 
were made, the tumorous and the adjacent non-
tumorous safe margin tissues. In addition, 14 adenoma 
patients were involved who underwent colonoscopical 
examination for checkup and then resection of 
adenomatous polyps and non-tumorous punch biopsies 
were taken from each one. CRC and adenoma patients 
were medically reviewed, the histopathological 
paraffin-embedded blocks were retrieved with complete 
histopathological and surgical reports. Written consents 
were obtained from all patients in this study. 
Histopathological paraffin blocks of excisional biopsies 
of 50 CRC and 14 adenoma patients were sectioned 
into 4 um thick on positively charged slides in order to 
be used later for the Immunohistochemistry assay 
(IHC).  
Am. J. Immunol., 4 (2): 14-22, 2008 
 
 16
Immunohistochemistry of p53, p21 and Ki-67 
proteins: Evaluation of the expression of p53, p21 and 
Ki-67 proteins in tumorous and non-tumerous tissues 
sections of CRC and in adenoma was done by using 
IHC. The procedure of IHC used was according to the 
manufacturer instructions (LSAB2 Universal 
Dakocytomation strepavidin-biotin detection system). 
Monoclonal antibodies used were, anti-p53 
(InnoGenex, USA), working dilution 1:100, anti-p21 
(DAKO, Denamark), working dilution 1:50 and anti-
Ki-67 (DAKO, Denamark), working dilution 1:100.  
 At every run of IHC for CRC, adenoma, one 
negative control tissue section, which is DW placed 
instead of the primary antibodies, one positive control 
tissue section, which is already tested as strongly 
positive.  
 After baking slides in oven at 65°C overnight, 
slides were deparaffinized by applying sequential 
immersion for 5 min in xylene, 95% ethanol, 70% 
ethanol and in DW respectively. In order to obtain the 
best results, autoclave-based antigen retrieval was done. 
Slides were placed in a jar containing antigen retrieval 
solution (0.1M citrate buffer, pH 6) and left in the 
autoclave, for 2-4 min under 121°C[37]. Then, 100 µL of 
the diluted primary antibody was applied onto the 
sections and the slides were placed in the humid 
chamber incubated at 4ºC overnight. The next day, 
slides were rinsed gently with PBS-Tween and placed 
in fresh PBS-Tween bath for 1 min. One-two drops of 
the biotinylated secondary goat anti-mouse antibodies 
(DakoCytomation) were applied onto the sections and 
slides were placed in the humid chamber and incubated 
at 37°C for 1 h. After rinsing step, One-two drops of 
streptaviden-Horseradish peroxidase (HRP) reagent 
(DakoCytomation) was applied onto the sections, slides 
were placed in humid chamber and incubated at 37ºC 
for 30 min. The prepared DAB-substrate chromogen 
solution was applied onto sections, Slides were 
incubated in dark at room temperature for 20 min. 
Mayer's hematoxylin stain was used as counterstain, 
then slides were dehydrated and mounted with DPX 
mounting fluid. 
 
Staining analysis: Expression of p53 and p21 proteins 
was assessed according to certain scoring system used 
by previous studies. Positively stained tumerous 
glandular cells, adenocarcinoma cells, out of non-
tumerous, normal glangular cells, were taken into 
account rather than stromal cells. The used scoring 
system is composed of 6 scores (0-5), Table 1. Tissue 
sections were regarded as p53 overexpression positive 
when immunoreactivity scores≥4, while p21  
Table 1: The scoring system used for the histopathological expression 
of both p53 and p21 proteins in CRC and adenoma tissue sections. 
 Negative Low     Positive (overexpression) 
 ----------- ------------------------------ ------------------------------- 
p53 Score 0 Score 1 Score 2 Score 3 Score 4 Score 5   
 0% 1-5%  5-15% 16-25% 26-75% >75%  
P21 Negative  Positive     
 0% 1-5% 5-15% 16-25% 26-75% >75%  
 
immunoreactivity was regarded as positive when 
percentages of stained cells ≥ 5%[38]. 
 Ki-67 index (KI) was used as a comparative 
measure for the level of Ki-67 expression among 
different tissue sections. KI estimated as the percentage 
obtained from the number of Ki-67 positively stained 
glandular cells over total glandular cells in 7-10 high 
power fields (total counted cells: about 1000)[39]. 
 
RESULTS 
 
Demographic and histopathological features of CRC 
and adenoma patients: The CRC patients pursued in 
this study were 27 men and 23 women with a mean age 
of 57.08 years (range between 43 and 76 years). 
Adenoma patients were 7 men and 7 women with a 
mean age of 50.1 years (range between 37 and 70 
years). All CRC cases were of adenocarcinoma, 32 
cases were left-sided, 12 right-sided and 6 at transverse 
colon .It was found that 6% of CRC patients were 
presented at B1 stage, 10% at B2 stage, 10% at C1 
stage, 14% at C2 stage and 60% at D stage. 
Furthermore, it was found that 60% of 
histolpathological sections of CRC patients were poorly 
differentiated and 40% were mild-moderate 
differentiated. For adenoma, it was found that 6 patients 
42.9% were of villous type, the most aggressive type of 
colon adenoma, size>2 cm, five patients (35.7%) were 
of tubulovillous type that is moderately aggressive, size 
0.8-1.5 cm, while only 3 patients (21.4%) were of 
tubular adenomatous polyps that is weakly aggressive, 
size 0.5-1.1 cm.  
 
Expression of p53, p21 and Ki-67 proteins in CRC 
and adenoma patients: The histopathological 
expression of p53 protein (Fig. 1) in the tumerous tissue 
sections of CRC and adenoma patients revealed that 39 
CRC patients (78%) and 2 adenoma patients (14.3%) 
showed p53 protein overexpression, the range of scores 
was 4 to 5, while none (0%) of the corresponding non-
tumerous tissue sections of both CRC and adenoma 
patients showed similar overexpression of p53 protein, 
the scores range was from 0-3, (Table 2).  
 The histopathological expression of p21 protein 
(Fig. 1)  revealed  that  17  CRC  patients  (34%)  and  9 
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Table 2: Frequency distribution of p53 and p21 expression scores in colorectal cancer and adenoma patients 
 Tumorous tissue sections  Non- Tumorous tissue sections 
 ---------------------------------------------------------------- ------------------------------------------------------------------ 
p53 staining  CRC patients N (%) Adenoma patients N (%) CRC patients N (%) Adenoma patients N (%)  
P53 negative: 
Score 0 (0%) 0 0 12 (24) 6 (42.86) 
Score 1 (1-5%) 0 1 (7.1) 10 (20) 4 (28.58) 
Score 2 (5-15%) 0 5 (35.7) 17 (34) 3 (21.42) 
Score 3 (16-25%) 11 (22) 6 (43) 11 (22) 1 (7.14) 
P53 positive: 
Score 4 (26-75%) 35 (70) 2 (14.3) 0 0 
Score 5 (>75%) 4 (8) 0 0 0 
Total  50(100) 14 (100) 50(100) 
 
 
 
Fig. 1: Immunohistochemical staining of colorectal 
carcinoma tissue sections showing positive 
signals by DAB stain counterstained with 
Meyers’ Hematoxylin.  (a) Positive Ki-67 
staining of CRC tissue section at X100 (b) The 
same field at X400. (c) Positive p53 staining 
(score 4) of CRC tissue section at X100 (d)  The 
same field at X400. (e) Positive p21 staining 
(score 3) of CRC tissue section at X100. (f) The 
same field t at X400 
 
adenoma patients (64.2%) showed positive p21 
expression, while it was shown that 48 out of 50 (96%) 
non-tumerous tissue sections of CRC patients and 14 
out of 14 (100%) non-tumerous tissue sections of 
adenoma patients were positive for p21 expression (the 
positively stained cells was >5%), (Table 3).  
 Chi-square and Fisher’s exact test were used for 
evaluating the difference in the level of expression of 
p53 and p21 proteins according to the scoring system 
adopted in this study. P53 protein overexpression was 
0% in the non-tumorous tissue sections of both CRC 
and adenoma patients in that overexpression of p53 was 
confined solely to the tumorous tissue sections of CRC 
and minimally to adenoma, indicating that the 
histologically normal tissues and most of the 
adenomatous cells still express p53 protein normally 
without exaggeration. On the contrary, the positive 
expression of p21 protein was extremely higher in the 
non-tumorous tissue sections, 48/50 patients (96%) in 
CRC and 14/14 (100%) in adenoma patients than the 
tumorous sections of the corresponding CRC, 34% and 
adenoma, 64% tissue sections (p<0.05).  
 Most importantly, it was found that p53 
overexpression (scores 4 and 5) in tumorous tissue 
sections of CRC patients was much higher than that of 
adenoma patients (p<0.0001). On the other hand, p21 
positive expression in tumorous tissue sections of CRC 
patients was much lower than that in adenoma patients 
(p = 0.04), (Fig. 2). Taken that, the positive control 
section of p53 was score 4 and the negative control 
section was score 0, while the positive control section 
of p21 was score 3 and the negative control section was 
score 0. 
 In order to validate the adapted scoring systems in 
this study and to keep a solid scientific results, 
quantitative statistical measures were applied using the 
percentage of the positively stained cells rather than the 
qualitative scoring systems. Student t- test results 
showed that the percentage of cells with p53 
overexpression in the tumorous tissue sections of CRC 
patients 46.04% was significantly higher than that of 
adenoma patients 17.92% (p<0.0001), (Fig. 2). For p21 
protein, Mann-Whitney test was used which showed the 
percentage of positively stained cells for p21 protein in 
the tumorous tissue sections of adenoma patients 
14.42% was significantly higher than that of CRC 
patients 6.06% (p = 0.014) (Fig. 2). 
 Pearsons’ correlation coefficient for p53 with p21 
in CRC patients showed that the correlation was 
inversely significant (r = - 0.37, p<0.01), which 
therefore clearly indicates that the higher the expression 
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Table 3: Frequency distribution of p21 expression scores in colorectal cancer and adenoma patients  
 Tumorous tissue sections  Non- Tumorous tissue sections 
 -------------------------------------------------------------------- -------------------------------------------------------------------- 
p21 staining  CRC patients N (%) Adenoma patients N (%) CRC patients N (%) Adenoma patients N (%) 
p21 negative:      
Score 0 (0%) 18 (36) 1 (7.1) 0 0 
Score 1 (1-5%) 15 (30) 4 (28.6) 2 (4) 0 
p21 positive:     
Score 2 (5-15%) 11 (22) 3 (21.4) 17 (34) 5 (35.72) 
Score 3 (16-25%) 4 (8) 3 (21.4) 18 (36) 6 (42.85) 
Score 4 (26-75%) 2 (4) 3 (21.4) 12 (24) 3 (21.43) 
Score 5 (>75%) 0 0 1 (2) 0 
Total 50 100) 14 (100) 50(100) 14(100) 
 
 
 
Fig. 2: Mean percentage of positively stained cells by 
immunohistochemistry assay for p53, p21 and 
Ki-67 in both CRC and adenoma patients 
of p53 in CRC patients the lower the expression of p21 
proteins and vice versa (Fig. 3).  
 Regarding Ki-67 and by using student t-test, it was 
found that Ki-67 expression index in CRC patients (KI 
60.28) was significantly higher than that in adenoma 
patients (KI 30.29) (p<0.0001) indicating that the 
proliferative index (KI) in CRC patients is far higher 
than that in adenoma patients, (Fig. 2). On the other 
hand, the non-tumorous tissue sections of CRC (KI 
8.34) and of adenoma (KI 7.64) were significantly 
lower than KI of the corresponding tumorous tissue 
sections (p<0.05). 
 
Expression of p21, p53 and Ki-67 with staging and 
grading of CRC: There was a significant difference of 
p21 protein expression among the studied groups of 
CRC staging (p<0.05) favoring stage B in which 6/8 
(75%), 4/12 (33.3%) at stage C and 8/30 (26.6%) at 
stage D were p21-positive. Furthermore, there was a 
significant  difference of p21 expression between 
poorly 7/30 (23.3%) and mild-moderate differentiated 
CRC   tissue   sections 10/20 (50%) (χ2 p = 0.05, Fisher  
 
 
Fig. 3: Correlation coefficient between p21 and p53 
expression, using Pearson/Spearman’s test 
 
p = 0.048). Regarding p53 and Ki-67, they were not 
related to the staging or the grading of CRC. 
 
DISCUSSION 
 
 There are two major pathways in colorectal 
carcinogenesis, the chromosomal instability pathway 
(adenoma-carcinoma sequence), which is characterized 
by allelic losses on chromosome 5q (APC), 17p (p53) 
and 18q (DCC/ SMAD4) and the other is a pathway 
that involves microsatellite instability[40]. In colon 
cancer, p53 gene on chromosome 17p is usually found 
to be mutated by partial deletions or mis-sense base 
changes, mainly located in four highly conserved 
regions of exons 5-8, such mutations have been 
observed in 30% of adenomas and 50-75% of 
carcinomas[31,41,42]. Wild-type p53 has a short half-life 
of about 15 min 22 and is turned over rapidly by an 
ATP-abiquitin degradation pathway and mutant p53 
protein has a greater stability with half-life prolonged 
up to 20 h[43]. In this study, p53 protein overexpression 
was found solely in the tumorous tissues rather than the 
adjacent histologically-normal tissues of both CRC and 
adenoma patients. It is noteworthy to mention that no 
previous study was conducted to explore the expression 
of p21 and p53 proteins in the histologically normal 
adjacent tissues to adenomas and CRC[30-36]. 
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Furthermore, p53 overexpression was found far higher 
in CRC tumor cells than adenoma cells indicating an 
exclusive role to play in the transformation process 
from normal colorectal mucosa, 0% overexpression, to 
premalignant adenoma, 14.3% overexpression and 
finally from adenoma to malignant carcinoma, 78% 
overexpression. These results are supported by another 
study[32] who stated that p53 positivity in CRC was 70% 
but they didn’t include the non-tumorous sections of 
CRC in the study nor adenoma tissue sections. On the 
contrary, another study[33] revealed that there is a 
complete absence of p53 expression in CRC which 
represents an adverse prognostic effect. 
 In order to investigate the controversial p53 
overexpression in CRC and since p21 protein was 
identified as the product of the gene activated by wild-
type p53[20], the immunohistochemical analysis of p21 
protein expression was studied and compared with that 
of p53 protein. According to the transcriptional 
activation of p53 towards p21, the level of p21 protein 
expression of both CRC and adenoma patients would 
clarifies whether p53 protein in CRC or adenoma 
tumors is dysfunctionally mutated or not. Our study 
showed that the expression of p21 protein was highest 
in the non-tumorous adjacent tissues to CRC and 
adenoma and was significantly higher than that of the 
tumorous sections (p<0.05). Moreover, it was higher in 
adenoma tumor cells than CRC tumor cells (p<0.05). 
These findings showed that p21 protein expression 
decreases with the progression of the transformational 
changes form normal mucosa to adenoma and from 
adenoma to carcinoma which is exactly the opposite to 
p53 protein expression. This indicates that p53 gene in 
CRC tumors was mutated and its protein became 
cryptic enough to not act as a competent transcriptional 
factor for p21 and its overexpression is most probably a 
compensatory mechanism. Moreover, the statistically 
significant inverse pearsons’ correlation observed in our 
study between p53 and p21 has confirmed this 
suggestion. Our results contradicted the results of 
previous studies[32,33] which revealed that no inverse 
correlation was found between p21 and p53, while[31,35] 
revealed such correlation.  
 Since mutated p53 is not found overtly 
overexpessed in adenoma such as the case in CRC, 
most of p53 proteins might still in the wild type as long 
as adenoma not yet converted to cancer and p53 
dysfunctional mutation seems to act most probably as 
the key for ending the curbing control of wild p53 
against the carcinogenetic tendencies initiated by the 
accumulation of a number of oncogens. In addition to 
the loss of p53 tumor suppressor function, p21 
downregulation as a consequence adds an additional 
breach to the tumor suppressor capability of the cells as 
Roninson et al. stated that p21 protein accounts for the 
induction of differentiation markers and mitosis 
inhibition, whereas subsequent downregulation could 
be related to mitotic catastrophe and cell proliferation 
would be unleashed[44].  
 Interestingly, our study revealed no association 
between p53 protein expression and CRC staging or 
grading, while p21 protein associated significantly with 
both staging and grading of CRC unlike the study[36] 
that revealed p21 has no relation to the staging of CRC 
and another study revealed that mutation of either p53 
or Ki-ras gene did not correlate with Dukes’s staging 
and tumor differentiation[45]. While other studies 
showed that the expression of p21 could be used as a 
marker to determine the degree of malignancy of 
colorectal and gastric cancers[46,31-33]. This might be 
explained by Yasui who stated that in colon cancer, 
abnormality of p21 genes is not found, but attenuation 
of expression of p21 genes is reported to be correlated 
with the degree of malignancy[47]. Since p21 protein is 
not under the strict impact of the two-hit theory of 
inactivation such as p53[48] and p21 protein showed a 
declining level of expression with the oncogenesis 
progression, so p21 level of expression has shown to be 
related to the degree of differentiation and staging of 
malignancy quantitatively. 
 The proportion of Ki-67 labeled cells in a given 
cell population (Ki-67 index) provides a measure of the 
growth fraction[49]. Our results showed the proliferative 
index (KI) in the tumorous sections of CRC patients 
was far higher than that in adenoma patients. This was 
another player might help understanding the nature of 
interplay between p53 and p21 in CRC and adenomas. 
At adenoma stage, the growth is still under control 
represented by values of KI when the wild p53 
expression is still not overtly overexpressed and the 
expression level of p21 is still relatively high. On the 
contrary in CRC, the dysfunctional p53 overexpression 
is seen widely along with a sharp decline in p21 
expression and sharp upsurge of the growth of tumor 
cells. This plot refers to the vital role of tumor 
suppressor proteins might play in the carcinogenesis of 
colorectal mucosa.  
 Accordingly, it was concluded from our study that 
p53 overexpresses in CRC more than in adenoma and 
in adenoma more than in normal tissues significantly. 
This overexpression is shown to act as a compensatory 
mechanism for the functional impairment of the wild 
p53. And the conversion of wild p53 to the 
dysfunctionally mutant and overexpressed p53 most 
probably act as a threshold for the conversion from 
benign premaligant tumor, adenoma, to overtly 
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malignant tumor, CRC. And this role of p53 was 
understood and confirmed by the associated crippling 
behavior of p21 which in turn has been quantitively 
lowered to a very shallow level in CRC that cripples 
even more the overall lowered tumor suppressor 
potential of the affected cells. This study showed that 
the histologically-normal adjacent tissues express the 
normal high levels of p21 protein and the normal levels 
of p53 protein although many studies confirmed that the 
adjacent tissues of adenoma or CRC are full of 
oncogens[5,9,11,12,14,42]. This sheds light to the exclusive 
need by the colorectal mucosal cells to the functional 
impairment/overexpression of p53 and the grave 
decrease in p21 to unleash these oncogens to transform 
normal cells to tumor cells and later to malignant cells. 
This study also confirmed the significance of the 
transcriptional activatory role of the wild type p53 
towards p21 expression. Furthermore, p21 level of 
expression seems to be a reliable index for the 
evaluation of the disease prognosis and the staging 
unlike p53. We recommend involving other 
carcinogenetic factors in the future studies like p27, 
COX-2, PGE2, TGF-beta, beta-catanin and APC using 
larger samples of adenoma/CRC patients and 
correlating their role in the adenoma-carcinoma 
transformation to that of the currently shown interplay 
of p53 and p21 in the progression of colorectal tumors. 
Moreover, we recommend focusing more on p53 and 
p21 proteins as potential targets for any futuristic CRC 
therapy whatever the type of accumulated oncogenes 
were because this study confirmed that the 
transformation process of adenoma to carcinoma needs 
by all means the currently shown p35/p21 interplay in 
order to proceed further in the transformation pathway 
reaching to the level of malignancy.  
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